Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NVNAMS +1.05%45 Altman Z-Score is 25.51 as of Aug. 08, 2026, which is 71% above its 10-year median of 14.91. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 931 Biotechnology companies, NewAmsterdam Pharma Co NV ranks better than 90.98% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 25.23 is strong.
NewAmsterdam Pharma Co NV has a Altman Z-Score of 25.51, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's Altman Z-Score or its related term are showing as below:
NAMS'
s Altman Z-Score Range Over the Past 10 Years
Min: 7.58 Med: 14.91 Max: 32.98
Current: 25.23
During the past 6 years, NewAmsterdam Pharma Co NV's highest Altman Z-Score was 32.98. The lowest was 7.58. And the median was 14.91.
NewAmsterdam Pharma Co NV (NAS:NAMS) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAMS vs ARQT, IDYA, ALMS: Altman Z-Score Comparison
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's Altman Z-Score falls into.
NewAmsterdam Pharma Co NV Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
NewAmsterdam Pharma Co NV (NAMS) has a Altman Z-Score of 25.51 as of Aug. 08, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on NewAmsterdam Pharma Co NV and its competitors. This is 71% above median its historical median of 14.91. Over the past decade, NewAmsterdam Pharma Co NV's Altman Z-Score has ranged from 7.58 to 32.98. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #84 out of 931 companies in the Biotechnology industry, placing it in the top 9%.
Is NewAmsterdam Pharma Co NV's Altman Z-Score too high?
NewAmsterdam Pharma Co NV's current Altman Z-Score of 25.51 is 71% above median its 10-year median of 14.91. Over the past 10 years, this metric has ranged from a low of 7.58 to a high of 32.98. The Biotechnology industry median Altman Z-Score is 2.39. NewAmsterdam Pharma Co NV's value of 25.51 is 967.4% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #84 out of 931 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Altman Z-Score compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #84 out of 931 companies for Altman Z-Score. This places NewAmsterdam Pharma Co NV in the top 9% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.39. NewAmsterdam Pharma Co NV's value of 25.51 is 967.4% above this benchmark. Historically, NewAmsterdam Pharma Co NV's own Altman Z-Score has ranged from 7.58 to 32.98 over the past decade. While the company's 10-year median is 14.91 vs. the industry median of 2.39, NewAmsterdam Pharma Co NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.39, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current Altman Z-Score of 25.51 is 967.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on NewAmsterdam Pharma Co NV and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Altman Z-Score is 25.51, which is 71% above median its own 10-year median of 14.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Altman Z-Score is 25.51, which is 71% above median its 10-year median of 14.91 and 967.4% above the Biotechnology industry median of 2.39. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Altman Z-Score is 25.51 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
Altman Z-Score: 25.51 (71% above median its 10-year median of 14.91)
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
Industry Position: 967.4% above the Biotechnology median (#84 of 931)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
